SPOTLIGHT -
Carflizomib: A second-generation proteasome inhibitor for the treatment of myeloma
The introduction of the immunomodulatory drugs and bortezomib, a proteasome inhibitor, has dramatically improved outcomes in patients with relapsed or refractory multiple myeloma.